

Helena Ramos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/261476/publications.pdf>

Version: 2024-02-01

17
papers

368
citations

759233

12
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

635
citing authors

#	ARTICLE	IF	CITATIONS
1	Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. <i>Cancer Letters</i> , 2022, 525, 131-145.	7.2	10
2	A selective p53 activator and anticancer agent to improve colorectal cancer therapy. <i>Cell Reports</i> , 2021, 35, 108982.	6.4	20
3	Structural and Drug Targeting Insights on Mutant p53. <i>Cancers</i> , 2021, 13, 3344.	3.7	38
4	A Diarylpentanoid with Potential Activation of the p53 Pathway: Combination of <i>in silico</i> Screening Studies, Synthesis, and Biological Activity Evaluation. <i>ChemMedChem</i> , 2021, 16, 2969-2981.	3.2	7
5	SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129440.	2.4	13
6	BRCA1/P53: Two strengths in cancer chemoprevention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188339.	7.4	17
7	p73: From the p53 shadow to a major pharmacological target in anticancer therapy. <i>Pharmacological Research</i> , 2020, 162, 105245.	7.1	15
8	SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner. <i>International Journal of Molecular Sciences</i> , 2020, 21, 596.	4.1	17
9	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1151.	3.7	21
10	Naphthoylhydrazones: coordination to metal ions and biological screening. <i>New Journal of Chemistry</i> , 2019, 43, 17801-17818.	2.8	13
11	Strategies to Discover p53 Activators and a p73 Activator for Neuroblastoma. <i>Proceedings (mdpi)</i> , 2019, 22, .	0.2	0
12	New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. <i>Cancer Letters</i> , 2019, 446, 90-102.	7.2	36
13	A simple linearization method unveils hidden enzymatic assay interferences. <i>Biophysical Chemistry</i> , 2019, 252, 106193.	2.8	6
14	p53 and glucose metabolism: an orchestra to be directed in cancer therapy. <i>Pharmacological Research</i> , 2018, 131, 75-86.	7.1	83
15	DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. <i>Molecular Oncology</i> , 2017, 11, 612-627.	4.6	33
16	p53 family interactions and yeast: together in anticancer therapy. <i>Drug Discovery Today</i> , 2016, 21, 616-624.	6.4	11
17	Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction. <i>Life Sciences</i> , 2015, 142, 60-65.	4.3	28